Engineering the Cyclization Loop of MCoTI-II Generates Targeted Cyclotides that Potently Inhibit Factor XIIa.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c01080
Abstract: Factor XIIa (FXIIa) is a promising target for developing new drugs that prevent thrombosis without causing bleeding complications. A native cyclotide (MCoTI-II) is gaining interest for engineering FXIIa-targeted anticoagulants as this peptide inhibits FXIIa but… read more here.
Keywords: loop; mcoti; cyclization loop; factor xiia ... See more keywords
Discovery of Highly Selective, Potent, Covalent, and Orally Bioavailable Factor XIIa Inhibitors for the Treatment of Thrombo-Inflammation.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.4c00475
Abstract: Thrombo-inflammation is closely associated with a few severe cardiovascular and infectious diseases. Factor XIIa (FXIIa) in the intrinsic coagulation pathway plays a pivotal role in the development of thrombo-inflammation and its inhibition has emerged as… read more here.
Keywords: potent covalent; thrombo inflammation; factor xiia; discovery highly ... See more keywords
New Triazole-Based Potent Inhibitors of Human Factor XIIa as Anticoagulants
Sign Up to like & getrecommendations! Published in 2024 at "ACS Omega"
DOI: 10.1021/acsomega.3c09335
Abstract: Factor XIIa (FXIIa) functions as a plasma serine protease within the contact activation pathway. Various animal models have indicated a substantial role for FXIIa in thromboembolic diseases. Interestingly, individuals and animals with FXII deficiency seem… read more here.
Keywords: factor xiia; triazole based; inhibitors human; fxiia ... See more keywords
Dual Inhibition of Factor XIIa and Factor XIa Produces a Synergistic Anticoagulant Effect
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Cardiovascular Pharmacology"
DOI: 10.1097/fjc.0000000000001573
Abstract: Supplemental Digital Content is Available in the Text. Abstract: Clinical practice shows that a critical unmet need in the field of thrombosis prevention is the availability of anticoagulant therapy without bleeding risk. Inhibitors against FXIa… read more here.
Keywords: dual inhibition; factor xiia; bleeding risk; inhibition factor ... See more keywords
Introduction to current issue.
Sign Up to like & getrecommendations! Published in 2017 at "Current Opinion in Hematology"
DOI: 10.1097/moh.0000000000000370
Abstract: DOI:10.1097/MOH.0000000000000370 As an introduction to my inaugural issue as associate editor for hemostasis and thrombosis of Current Opinion in Hematology, I want to present the themes that comprise this year’s edition. The field of hemostasis… read more here.
Keywords: issue; hematology; factor xii; factor xiia ... See more keywords